电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant CD22 (Epratuzumab Biosimilar) 抗体

适用: Cynomolgus, 人, 猕猴 BP, FACS, IP 宿主: Human Monoclonal hL22 unconjugated Recombinant Antibody
产品编号 ABIN5668216
发货至: 中国
  • 抗原 See all CD22 (Epratuzumab Biosimilar) products
    CD22 (Epratuzumab Biosimilar)
    抗体类型
    Recombinant Antibody
    适用
    Cynomolgus, 人, 猕猴
    宿主
    • 1
    Human
    克隆类型
    • 1
    单克隆
    标记
    • 1
    This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
    应用范围
    Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)
    特异性
    This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
    产品特性

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    纯化方法
    Purified antibody.
    纯度
    > 98 % as determined by SDS-PAGE
    内毒素水平
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    免疫原
    This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
    克隆位点
    HL22
    亚型
    IgG1 kappa
  • 应用备注
    Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
    限制
    仅限研究用
  • 缓冲液
    PBS with 0.02 % Proclin 300.
    储存液
    ProClin
    注意事项
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    储存条件
    4 °C,-20 °C
    储存方法
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • 抗原
    CD22 (Epratuzumab Biosimilar)
    Abstract
    CD22 (Epratuzumab Biosimilar) 产品
    别名
    SIGLEC-2 antibody, SIGLEC2 antibody, CD22 molecule antibody, CD22 antibody
    物质类
    Biosimilar
    背景
    Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
    UniProt
    P20273
You are here:
客服